|1.||Hara, Hideaki: 4 articles (10/2013 - 01/2010)|
|2.||Shimazawa, Masamitsu: 4 articles (10/2013 - 01/2010)|
|3.||Tsuruma, Kazuhiro: 4 articles (10/2013 - 01/2010)|
|4.||Luft, Friedrich C: 3 articles (10/2015 - 10/2010)|
|5.||Klussmann, Enno: 3 articles (10/2015 - 03/2015)|
|6.||Degerman, Eva: 3 articles (03/2015 - 04/2004)|
|7.||Mishiro, Keisuke: 3 articles (10/2013 - 01/2010)|
|8.||Sanganalmath, Santosh K: 3 articles (09/2008 - 01/2008)|
|9.||Barta, Judit: 3 articles (09/2008 - 01/2008)|
|10.||Dhalla, Naranjan S: 3 articles (09/2008 - 01/2008)|
06/01/1991 - "Phosphodiesterase III inhibitors work independent of adrenoreceptor activity and plasma catecholamine levels; thus these agents are likely to be more effective in the treatment of severe heart failure. "
03/01/2006 - "Several clinical studies suggest substantial limitations of currently available positive inotropic substances, including beta1-adrenoceptor agonists and phosphodiesterase III inhibitors in the short- and long-term treatment of heart failure. "
01/01/2005 - "Phosphodiesterase III inhibitors for heart failure."
09/13/2003 - "In the treatment of patients with acute heart failure, phosphodiesterase III-inhibitors are becoming part of standard therapy in addition to beta-adrenoceptor agonists, especially in patients who take beta-blockers."
08/07/2001 - "Phosphodiesterase III inhibitors (PDEIII-Is) improve the hemodynamic status of heart failure via inotropic/vasodilatory effects attributable to the increase in intracellular cAMP level. "
03/01/2002 - "Treatment with the phosphodiesterase III inhibitor, cilostazol, has been shown to improve walking distances significantly in diabetes patients with intermittent claudication and also appears to improve plasma lipid profiles. "
07/01/1999 - "Cilostazol is a phosphodiesterase III inhibitor that has been shown to be effective for treatment of symptomatic intermittent claudication. "
10/01/2009 - "Cilostazol is a phosphodiesterase III inhibitor with a firm evidence base for use in intermittent claudication. "
08/15/2009 - "Cilostazol, a drug commonly used in the treatment of intermittent claudication is a selective phosphodiesterase III inhibitor. "
02/01/2008 - "Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD). "
12/01/1991 - "Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism."
11/15/1999 - "Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery."
11/15/1999 - "The present study was conducted to determine the ability of cilostazol, a phosphodiesterase III inhibitor, to prevent formation of totally occlusive thrombus in a porcine carotid artery, in comparison with ticlopidine. "
02/01/2006 - "Cilostazol is a phosphodiesterase III inhibitor with pharmacological effects that include vasodilation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth. "
01/14/2009 - "Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction."
06/01/2003 - "Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction."
01/14/2009 - "Following the improvement of cardiac function and ventricular remodeling, ICER and CREB mRNA in pre- and post- myocardial-infarction groups were down-regulated, and phosphodiesterase 3A and Bcl-2 mRNA were up-regulated (P<0.05). "
01/14/2009 - "To investigate the changes of inducible cAMP early repressor (ICER) and phosphodiesterase 3A in rats after myocardial infarction and to evaluate the beneficial effects of valsartan on cardiac function and ventricular remodeling. "
02/01/1994 - "The aim of this study was to determine whether viable myocardium can be identified by two-dimensional echocardiography after an i.v. bolus of enoximone-positive inotropic non-adrenergic drug, phosphodiesterase III inhibitor as well as during dobutamine infusion, in patients with acute myocardial infarction. "
|4.||Vasodilator Agents (Vasodilators)
|10.||Adenosine Triphosphate (ATP)
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)